Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$5.87
-0.13-2.25%
Last update: Jul 14, 2:41 PM
Vanda Pharmaceuticals Inc Analyst Ratings
VNDANASDAQ
Vanda Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:VNDA | Benzinga
Vanda Pharmaceuticals Inc has a consensus price target of $14.08 based on the ratings of 6 analysts. The high is $21 issued by HC Wainwright & Co. on May 11, 2026. The low is $7.5 issued by Jefferies on December 31, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Truist Securities, and HC Wainwright & Co. on May 11, 2026, March 5, 2026, and February 23, 2026, respectively. With an average price target of $21 between HC Wainwright & Co., Truist Securities, and HC Wainwright & Co., there's an implied 258.06% upside for Vanda Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Truist Securities
B. Riley Securities
Jefferies
Cantor Fitzgerald
1calculated from analyst ratings
Analyst Ratings for Vanda Pharmaceuticals
Loading calendar...
FAQ
What is the target price for Vanda Pharmaceuticals (VNDA) stock?
The latest price target for Vanda Pharmaceuticals (NASDAQ:VNDA) was reported by HC Wainwright & Co. on May 11, 2026. The analyst firm set a price target for $21.00 expecting VNDA to rise to within 12 months (a possible 258.06% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Vanda Pharmaceuticals (VNDA)?
The latest analyst rating for Vanda Pharmaceuticals (NASDAQ:VNDA) was provided by HC Wainwright & Co., and Vanda Pharmaceuticals maintained their buy rating.
When was the last upgrade for Vanda Pharmaceuticals (VNDA)?
There is no last upgrade for Vanda Pharmaceuticals
When was the last downgrade for Vanda Pharmaceuticals (VNDA)?
There is no last downgrade for Vanda Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Vanda Pharmaceuticals (VNDA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vanda Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vanda Pharmaceuticals was filed on May 11, 2026 so you should expect the next rating to be made available sometime around May 11, 2027.
Is the Analyst Rating Vanda Pharmaceuticals (VNDA) correct?
While ratings are subjective and will change, the latest Vanda Pharmaceuticals (VNDA) rating was a maintained with a price target of $24.00 to $21.00. The current price Vanda Pharmaceuticals (VNDA) is trading at is $5.87, which is out of the analyst’s predicted range.
